Literature DB >> 11788695

Outcome and prognostic factors of restenosis after percutaneous treatment of native hemodialysis fistulas.

Timothy W I Clark1, David A Hirsch, Kailash J Jindal, Paul J Veugelers, John LeBlanc.   

Abstract

PURPOSE: To assess patency after percutaneous treatment of dysfunctional and thrombosed native arteriovenous fistulas and to examine predictors of patency after intervention.
MATERIALS AND METHODS: A cohort of 65 consecutive patients with dysfunctional (n = 53) or occluded (n = 12) native fistulas who underwent 96 percutaneous interventions over an 18-month period was retrospectively analyzed. Fistula locations were radiocephalic (n = 37), brachiocephalic (n = 10), or brachiobasilic (n = 18). Primary interventions consisted of angioplasty (n = 50), stent placement (n = 3), or percutaneous thrombolysis/thrombectomy (n = 12). Additional interventions during follow-up consisted of angioplasty (n = 22), stent placement (n = 6), or percutaneous thrombolysis/thrombectomy (n = 3). Duration of fistula function was assessed clinically and examined as a function of anatomic and clinical variables with use of Cox hazards models and the Kaplan-Meier method.
RESULTS: Clinical success with resumption of at least one session of normal dialysis occurred in 94% (90 of 96) of interventions. The 30-day morbidity rate was 2.1%; no procedure-related deaths occurred. Primary, assisted primary, and secondary patency rates (+/- SE) of dysfunctional fistulas after intervention at 12 months were 26% +/- 11%, 80% +/- 6%, and 82% +/- 6%. Occluded fistulas after intervention had 3-month primary, assisted primary, and secondary patency rates of 60% +/- 15%, 60% +/- 15%, and 80% +/- 13%. Lesions 2.0 cm or more in length were five times more likely to have loss of patency than lesions smaller than 2.0 cm. The presence of at least one comorbid factor--diabetes, coronary artery disease, or peripheral vascular disease--was associated with nearly twice the risk of patency loss after any intervention.
CONCLUSION: Despite modest primary patency rates in our experience, high assisted and secondary patency rates can be achieved with percutaneous intervention in native arteriovenous fistulas. These findings emphasize the need for close surveillance of native fistulas and a low threshold for diagnostic fistulography after initial intervention. The most detrimental determinant of outcome was lesion length > or =2 cm.

Entities:  

Mesh:

Year:  2002        PMID: 11788695     DOI: 10.1016/s1051-0443(07)60009-8

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  22 in total

1.  Percutaneous transluminal angioplasty for dysfunctional femoral hemodialysis graft.

Authors:  Eunsun Oh; Yong Jae Kim; Dong Erk Goo; Seungboo Yang; Seongsook Hong
Journal:  Diagn Interv Radiol       Date:  2015 Mar-Apr       Impact factor: 2.630

2.  Optimizing function and treatment of hemodialysis grafts and fistulae.

Authors:  Thomas M Vesely
Journal:  Semin Intervent Radiol       Date:  2004-06       Impact factor: 1.513

3.  Percutaneous transluminal balloon angioplasty in stenosis of native hemodialysis arteriovenous fistulas: technical success and analysis of factors affecting postprocedural fistula patency.

Authors:  Ayse Aktas; Alper Bozkurt; Bulent Aktas; Ismail Kirbas
Journal:  Diagn Interv Radiol       Date:  2015 Mar-Apr       Impact factor: 2.630

4.  Deficiency of Endothelial Progenitor Cells Associates with Graft Thrombosis in Patients Undergoing Endovascular Therapy of Dysfunctional Dialysis Grafts.

Authors:  Tsung-Yan Chen; Lin Lin; Mu-Yang Hsieh; Jui-Cheng Kuo; Chia-Ling Wang; Ren-Huei Wang; Chao-Lun Lai; Po-Hsun Huang; Chih-Cheng Wu
Journal:  Acta Cardiol Sin       Date:  2017-01       Impact factor: 2.672

Review 5.  Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access.

Authors:  Gerald A Beathard; Charmaine E Lok; Marc H Glickman; Ahmed A Al-Jaishi; Donna Bednarski; David L Cull; Jeffery H Lawson; Timmy C Lee; Vandana D Niyyar; Donna Syracuse; Scott O Trerotola; Prabir Roy-Chaudhury; Surendra Shenoy; Margo Underwood; Haimanot Wasse; Karen Woo; Theodore H Yuo; Thomas S Huber
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-20       Impact factor: 8.237

6.  Autologous fat transplants to deliver glitazone and adiponectin for vasculoprotection.

Authors:  William G Sanders; Huan Li; Ilya Zhuplatov; Yuxia He; Seong-Eun Kim; Alfred K Cheung; Jayant Agarwal; Christi M Terry
Journal:  J Control Release       Date:  2017-09-01       Impact factor: 9.776

7.  Frequency of swing-segment stenosis in referred dialysis patients with angiographically documented lesions.

Authors:  Olurotimi J Badero; Moro O Salifu; Haimanot Wasse; Jack Work
Journal:  Am J Kidney Dis       Date:  2008-01       Impact factor: 8.860

8.  Plasma ADMA predicts restenosis of arteriovenous fistula.

Authors:  Chih-Cheng Wu; Szu-Chi Wen; Chung-Wei Yang; Shih-Yun Pu; Kuei-Chin Tsai; Jaw-Wen Chen
Journal:  J Am Soc Nephrol       Date:  2008-12-31       Impact factor: 10.121

9.  Similar degree of intimal hyperplasia in surgically detected stenotic and nonstenotic arteriovenous fistula segments: a preliminary report.

Authors:  Juan C Duque; Marwan Tabbara; Laisel Martinez; Angela Paez; Guillermo Selman; Loay H Salman; Omaida C Velazquez; Roberto I Vazquez-Padron
Journal:  Surgery       Date:  2017-12-11       Impact factor: 3.982

10.  Relationship of late arteriovenous fistula stenosis with soluble E-selectin and soluble EPCR in chronic hemodialysis patients with arteriovenous fistula.

Authors:  Mukadder Ayse Bilgic; Hakki Yilmaz; Alper Bozkurt; Huseyin Tugrul Celik; Ismail Celal Bilgic; Ozgul Malcok Gurel; Ismail Kirbas; Nuket Bavbek; Ali Akcay
Journal:  Clin Exp Nephrol       Date:  2014-03-14       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.